AstraZeneca

YTD

ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell AstraZeneca and other ETFs, options, and stocks.

About AZN

AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company’s history roots back to the year 1913 when Astra business was formed.

CEO

Pascal Soriot

CEOPascal Soriot

Employees

94,300

Employees94,300

Headquarters

Cambridge, Cambridgeshire

HeadquartersCambridge, Cambridgeshire

Founded

1913

Founded1913

Employees

94,300

Employees94,300

AZN Key Statistics

Market cap

267.75B

Market cap267.75B

Price-Earnings ratio

31.85

Price-Earnings ratio31.85

Dividend yield

1.80%

Dividend yield1.80%

Average volume

6.22M

Average volume6.22M

High today

$86.30

High today$86.30

Low today

$85.27

Low today$85.27

Open price

$85.42

Open price$85.42

Volume

3.49M

Volume3.49M

52 Week high

$86.57

52 Week high$86.57

52 Week low

$61.24

52 Week low$61.24

AZN News

TipRanks 5h

AstraZeneca’s AZD4144: Promising Obesity Treatment Under Study

AstraZeneca ((AZN)) announced an update on their ongoing clinical study. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 55% off! Unlock...

Benzinga 6h

AstraZeneca's Baxdrostat Shows Meaningful Blood Pressure Control In Patients With Resistant Hypertension

On Tuesday, AstraZeneca Plc (NASDAQ:AZN) released high-level results from the Bax24 Phase 3 trial to evaluate the safety, tolerability, and the effect of 2mg ba...

Investor's Business Daily 8h

Best Stocks To Watch: Two New IPOs, Pharma Titan AstraZeneca And Electrical Grid Play Emcor Trade Near Buy Points

Stocks Near A Buy Zone Best Stocks To Watch: Two New IPOs, Pharma Titan AstraZeneca And Electrical Grid Play Emcor Trade Near Buy Points Licensing The IPO secto...

Analyst ratings

81%

of 31 ratings

Buy

80.6%

Hold

19.4%

Sell

More AZN News

Nasdaq 15h

AZN : Baxdrostat Meets Primary Endpoint In Phase III Trial For Treatment-Resistant Hypertension

(RTTNews) - AstraZeneca (AZN, AZN.L,ZEG.DE,AZN.ST) announced that baxdrostat met the primary endpoint in the Bax24 Phase III trial, demonstrating a statisticall...

TipRanks 15h

AstraZeneca’s Baxdrostat Shows Promising Results in Hypertension Trial

Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to...

Benzinga 1d

AstraZeneca Taps Gene Editing And AI Platform For Drug Discovery For Immunology Diseases

Algen Biotechnologies, a privately held biotech company specializing in advanced CRISPR gene modulation and AI-driven drug discovery, has announced a multi-targ...

TipRanks 1d

AstraZeneca Stock Climbs on $555M AI Deal to Reverse Disease

Shares in pharmaceuticals giant AstraZeneca (AZN) edged higher today after striking a $555 million deal with U.S. biotech Algen Biotechnologies to develop AI-po...

Benzinga 1d

AstraZeneca/Daiichi Sankyo Partnered Breast Cancer Drug Shows Survival Benefit Over Chemotherapy

AstraZeneca Plc (NASDAQ:AZN) and Daiichi Sankyo on Monday released high-level results from the TROPION-Breast02 Phase 3 trial. The trial is evaluating Datroway...

Nasdaq 1d

AstraZeneca Reaches Analyst Target Price

In recent trading, shares of AstraZeneca plc (Symbol: AZN) have crossed above the average analyst 12-month target price of $85.09, changing hands for $85.31/sha...

TipRanks 2d

AstraZeneca reports improvement in dual primary endpoint of Datroway study

Topline results from the TROPION-Breast02 phase 3 trial showed Datroway demonstrated a statistically significant and clinically meaningful improvement for the d...